Delivery Order 36F79720D0017-36C25925F0204
Award Date
1/29/25
Potential Completion Date
2/3/25
Potential Value
$20K
Federal Agency
Veterans Integrated Service Network 19
Awardee
Dompe U.s. Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) awarded a $159,096.48 firm fixed price delivery order to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide the ophthalmic solution Oxervate for emergency patient treatment. This order was placed against Dompe's existing Pharmaceuticals and Drugs schedule contract (FSS-61-IB) with the General Services Administration (GSA). Dompe also holds a $2.4 million blanket purchase agreement with the VA National Acquisition Center specifically...
The U.S. Department of Veterans Affairs, through the Veterans Integrated Service Network 1, awarded a Firm Fixed Price Blanket Purchase Agreement (BPA) call to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide Oxervate ophthalmic solution medication. The contract, valued at $70,914.40, is funded through the VA's pharmaceutical and drugs acquisition schedule (FSS-61-IB). Dompe U.S. Inc. has provided Oxervate and other pharmaceutical products to the VA through various...
This is a delivery order contract awarded to Dompe U.S. Inc., a foreign-owned, for-profit pharmaceutical manufacturer, by the Department of Veterans Affairs (VA). The contract is for the provision of Oxervate, an ophthalmic solution used to treat neurotrophic keratitis, to VA facilities across the country. The contract is a firm fixed-price order placed against the General Services Administration (GSA) Pharmaceuticals and Drugs schedule (FSS-61-IB). The contract has a ceiling value of $19,887.06...
This is a delivery order awarded to Dompe U.S. Inc., a foreign-owned for-profit pharmaceutical manufacturer, by the U.S. Department of Veterans Affairs (VA) under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule contract (FSS-61-IB). The order, valued at $38,614.40, is for the delivery of Oxervate, an ophthalmic solution used to treat neurotrophic keratitis, to VA facilities. Dompe U.S. Inc. has received multiple similar orders against this GSA schedule contract to...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution. The $39,774.12 order was placed against Dompe's existing General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract (FSS-61-IB). Oxervate is an ophthalmic product used to treat neurotrophic keratitis. This order does not have a set-aside designation....
This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule contract (FSS-61-IB). The order is for the supply of Oxervate, an ophthalmic solution used to treat neurotrophic keratitis, to VA facilities across the country. The delivery order has a ceiling value of $38,614.40 and a period of performance ending on...
This is a delivery order awarded by the Department of Veterans Affairs (VA) to Dompe U.S. Inc., a foreign-owned, for-profit pharmaceutical manufacturer, against the General Services Administration (GSA) Pharmaceuticals and Drugs schedule (FSS-61-IB). The $19,887.06 firm fixed price order is for the supply of Oxervate, an ophthalmic solution used to treat neurotrophic keratitis. This award is not set-aside and is part of a larger $2.4 million blanket purchase agreement Dompe holds with the VA...
This is a firm fixed-price delivery order awarded by the Veterans Integrated Service Network (VISN) 22 to the foreign-owned, for-profit pharmaceutical manufacturer Dompe U.S. Inc. The order is for the ophthalmic drug Oxervate 0.002% and was placed against Dompe's General Services Administration (GSA) Pharmaceuticals and Drugs schedule contract (FSS-61-IB). The contract has a ceiling value of $19,307.20 and a period of performance through March 14, 2025. Dompe U.S. Inc. is providing Oxervate to...
This federal contract award is for the provision of the ophthalmic solution Oxervate to the U.S. Department of Veterans Affairs (VA) through a delivery order against the General Services Administration (GSA) Pharmaceuticals and Drugs schedule (FSS-61-IB). The prime contractor is Dompe U.S. Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $19,887.06 and an ultimate completion date of February 15, 2025. This contract does not have a set-aside...
This federal contract award is for the delivery of Oxervate, an ophthalmic solution used to treat neurotrophic keratitis, to the Department of Veterans Affairs (VA). The contract was awarded to Dompe U.S. Inc., a foreign-owned, for-profit pharmaceutical manufacturer, through the GSA Pharmaceuticals and Drugs schedule (FSS-61-IB). The firm fixed-price delivery order has a ceiling value of $38,614.40 and an ultimate completion date of November 29, 2024. This award is not associated with a...